No matches
Rhinology

ERS-ISIAN 2025 | Type 2 Inflammation: Links with Severe/Uncontrolled CRSwNP

Prof. Vibeke Backer provides an insightful presentation on the association of type 2 inflammation and the pathogenesis and management of severe and uncontrolled CRSwNP.
Vibeke Backer
DMSc, MD
Vibeke Backer

Related resources

EAACI 2024 Moving Beyond Control To On-Treatment Clinical Remission

EAACI 2024 Moving Beyond Control To On-Treatment Clinical Remission

expert video
AANP 2025 | Atopic Diseases & a Case-Based Panel of Nurse Practitioners

AANP 2025 | Atopic Diseases & a Case-Based Panel of Nurse Practitioners

videoanimation
ERS-ISIAN 2025 | Disease Control in CRSwNP

ERS-ISIAN 2025 | Disease Control in CRSwNP

expert video
ERS-ISIAN 2025 | Treatable Traits in CRSwNP

ERS-ISIAN 2025 | Treatable Traits in CRSwNP

expert video

Description

Prof. Backer will expertly navigate the intricate relationship between Type 2 inflammation and the most challenging forms of CRSwNP. This presentation will move beyond symptomatic management to explore the fundamental immunological pathways that contribute to disease severity and disease relapse.

Tags
disease controlCRSwNPpatient burdendisease severityacute exacerbations
MAT-GLB-2504853 - 1.0 - 09/2025

About this expert

Pulmonology

Vibeke Backer

DMSc, MD

Chief Respiratory Physician, Department of ENT and Centre for Physical Activity Research | Rigshospitalet, Copenhagen, Denmark

See author’s profile
Vibeke Backer

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: GreeceChange country/region